Public perception of participation in low-risk clinical trials in critical care using waived consent: a Canadian national survey

Public perception of participation in low-risk clinical trials in critical care using waived consent: a Canadian national survey
Dawn Opgenorth, D’Arcy J. Duquette, Linda Tyre, Robyn Auld, Kim Crowder, Peggy Gilchrist, Paul J. Young, Sean M. Bagshaw
Canadian Journal of Anesthesia, 8 March 2024
Abstract
Purpose
The acceptability of waiver of consent for participation in clinical research in intensive care unit (ICU) settings is uncertain. We sought to survey the Canadian public to assess levels of support, comfort, and acceptability for waived consent for low-risk clinical trials.
Methods
We performed a prospective cross-sectional survey of the Canadian public aged 18 yr or older. The survey was conducted by Ipsos between 19 and 23 November 2020. The survey content was derived from a literature review and in consultation with a patient and family partnership committee. The survey focused on attitudes and beliefs on waived consent for participation in low-risk clinical trials in ICU settings. The survey contained 35 items focused on sociodemographics, general health status, participation in medical research, and levels of support and comfort with research and with waived consent. The survey used a case study of a low-risk clinical trial intervention in ICU patients. Analysis was descriptive.
Results
We included 2,000 participants, 38% of whom reported experience with ICU and 16% with medical research. Participation in medical research was more common among those with postsecondary education, those with chronic disease, and those who were employed in health care. Most (80%) would support a model of waived consent for low-risk clinical trials, citing medical benefits (36%) and low perceived risk (34%). Most (77%) were comfortable with personally participating in a low-risk clinical trial. Most (80%) believed waived consent approaches were acceptable. Half (52%) believed the waived consent process should provide information about the research and include the option of opting out. When asked whether participants should always give full informed consent, regardless of the practicality or level of risk, 74% and 72% agreed, respectively.
Conclusions
There is public support for models of waived consent for participation in low-risk pragmatic clinical trials in ICU settings in Canada; however, this is not universal. This information can inform and guide education, ethics, policy, and legal discussion on consent models.

Public support for and concerns regarding pediatric dose optimization for seizures in emergency medical services: An exception from informed consent (EFIC) trial

Public support for and concerns regarding pediatric dose optimization for seizures in emergency medical services: An exception from informed consent (EFIC) trial
Ward CE, Adelgais KM, Holsti M, Jacobsen KK, Simon HK, Morris CR, Gonzalez VM, Lerner G, Ghaffari K, VanBuren JM, Lerner EB, Shah MI
Academic Emergency Medicine, 7 March 2024
Abstract
Background
Federal regulations allow exception from informed consent (EFIC) to study emergent conditions when obtaining prospective consent is not feasible. Little is known about public views on including children in EFIC studies. The Pediatric Dose Optimization for Seizures in EMS (PediDOSE) trial implements age-based, standardized midazolam dosing for pediatric seizures. The primary objective of this study was to determine public support for and concerns about the PediDOSE EFIC trial. The secondary objective was to assess how support for PediDOSE varied by demographics.
Methods
We conducted a mixed-methods study in 20 U.S. communities. Participants reviewed information about PediDOSE before completing an online survey. Descriptive data were generated. Univariable and multivariable logistic regression analysis identified factors associated with support for PediDOSE. Reviewers identified themes from free-text response data regarding participant concerns.
Results
Of 2450 respondents, 79% were parents/guardians, and 20% had a child with previous seizures. A total of 96% of respondents supported PediDOSE being conducted, and 70% approved of children being enrolled without prior consent. Non-Hispanic Black respondents were less likely than non-Hispanic White respondents to support PediDOSE with an adjusted odds ratio (aOR) of 0.57 (95% CI 0.42-0.75). Health care providers were more likely to support PediDOSE, with strongest support among prehospital emergency medicine clinicians (aOR 5.82, 95% CI 3.19-10.62). Age, gender, parental status, and level of education were not associated with support of PediDOSE. Common concerns about PediDOSE included adverse effects, legal and ethical concerns about enrolling without consent, and potential racial bias.
Conclusions
In communities where this study will occur, most respondents supported PediDOSE being conducted with EFIC and most approved of children being enrolled without prior consent. Support was lowest among non-Hispanic Black respondents and highest among health care providers. Further research is needed to determine optimal ways to address the concerns of specific racial and ethnic groups when conducting EFIC trials.

Ethical Challenges with the Informed Consent Process in Pediatric Research Studies

Ethical Challenges with the Informed Consent Process in Pediatric Research Studies
Thabit S. Alotaibi
Medical Archives, 2024; 78(1) pp 65-67
Abstract
Background
Informed Consent (IC) is crucial in pediatric research, aligning with the National Research Act of 1974 and the Belmont Report’s principles. Current regulations, particularly 45 CFR 46, provide additional safeguards for children in research.
Objective
This article explores ethical challenges in pediatric research IC, drawing from PubMed literature and regulatory guidelines to understand historical context, legislative milestones, and contemporary issues.
Methods
A literature review, primarily sourced from PubMed, informed the examination of pediatric research and IC, referencing guidelines from the American Academy of Pediatrics and regulations from the FDA and HHS.
Results
The study underscores the need for increased pediatric research due to the prevalence of drugs studied on adults. Despite legislative efforts like the FDAMA and Pediatric Research Equity Act, ethical challenges persist in obtaining IC in pediatric studies.
Conclusion
Pediatric research necessitates nuanced IC approaches, involving parents, guardians, and children. Ethical challenges such as coercion and compensation require attention, with recommendations emphasizing guideline adherence and increased public engagement for trust-building and pediatric health advancement.

Shaping the future of AI in healthcare through ethics and governance

Shaping the future of AI in healthcare through ethics and governance
Rabaï Bouderhem
Humanities and Social Sciences Communications, 15 March 2024
Open Access
Abstract
The purpose of this research is to identify and evaluate the technical, ethical and regulatory challenges related to the use of Artificial Intelligence (AI) in healthcare. The potential applications of AI in healthcare seem limitless and vary in their nature and scope, ranging from privacy, research, informed consent, patient autonomy, accountability, health equity, fairness, AI-based diagnostic algorithms to care management through automation for specific manual activities to reduce paperwork and human error. The main challenges faced by states in regulating the use of AI in healthcare were identified, especially the legal voids and complexities for adequate regulation and better transparency. A few recommendations were made to protect health data, mitigate risks and regulate more efficiently the use of AI in healthcare through international cooperation and the adoption of harmonized standards under the World Health Organization (WHO) in line with its constitutional mandate to regulate digital and public health. European Union (EU) law can serve as a model and guidance for the WHO for a reform of the International Health Regulations (IHR).

Consent and Identifiability for Patient Images in Research, Education, and Image-Based Artificial Intelligence

Consent and Identifiability for Patient Images in Research, Education, and Image-Based Artificial Intelligence
Research Letter
Trina Salvador, Lilly Gu, Jennifer L. Hay, Nicholas R. Kurtansky, Ruth Masterson-Creber, Allan C. Halpern, Veronica Rotemberg
JAMA Dermatology, 13 March 2024
Abstract
Increasing use of imaging for research, education, and development of image-based artificial intelligence (AI) is parallel to increasing concerns about confidentiality and autonomy. Regulatory requirements for collecting and processing personal information vary geographically, but even the most stringent legal guidelines do not require informed consent for sharing of deidentified data. Despite widespread use of imaging in dermatology and portability of digital image formats that enable both rapid intentional and inadvertent image sharing, information about attitudes and preferences on consent and identifiability are limited. Consequently, processes for obtaining informed consent are not standardized across clinical practices and research journals.4 To inform practices for protecting privacy, we performed a survey study to elucidate perspectives on image use, consent, and identifiability.

An In-Depth Qualitative Interview: The Impact of Artificial Intelligence (AI) on Consent and Transparency

An In-Depth Qualitative Interview: The Impact of Artificial Intelligence (AI) on Consent and Transparency
Book Chapter
Sharon L. Burton, Darrell N. Burrell, Calvin Nobles, Yoshino W. White, Maurice E. Dawson, Kim L. Brown-Jackson, S Rachid Muller, Dustin I. Bessette
Multisector Insights in Healthcare, Social Sciences, Society, and Technology, 2024 [IGI Global]
Abstract
AI is impacting consent and transparency adversely. Although AI can potentially augment transparency in decision-making via advanced technology, it is creating new concerns. This chapter focuses on the impact of AI systems on individuals’ ability to provide informed consent for using their data, and the relationship between transparency in AI decision-making processes and issues related to accountability and trust. Discussed are GDPR (European Union General Data Protection Regulation), and CCPA (California Consumer Privacy Act) due to their consent and transparency within their broader privacy protection frameworks. Applied is a qualitative methodology and in-depth interview design using a communication and collaboration platform to explain the connection between AI consent and transparency. Research results offer avenues to understanding the challenges of informed consent and legal and ethical considerations regarding consent and transparency. Beneficiaries of this research are practitioners, academics, and learners in AI, cybersecurity, and criminology/criminal justice.

Attitude towards consent-free research use of personal medical data in the general German population

Attitude towards consent-free research use of personal medical data in the general German population
Research Article
Gesine Richter, Nourane Trigui, Amke Caliebe, Michael Krawczak
Heliyon, 30 March 2024; 10(6)
Open Access
Abstract
Background
The design of appropriate consent procedures for the secondary use of personal health data is a key concern of current medical research. In Germany, the concept of ‘data donation’ has recently come into focus, defined as a legal entitlement to the research use of personal medical data without prior consent, combined with an easy-to-exercise right of the data subjects to opt-out.
Methods
Standardized online interviews of 3,013 individuals, representative of the German online population, were conducted in
August 2022 to determine their attitude towards data donation for medical research.
Results
A majority of participants supported a consent-free data donation regulation, both for publicly funded (85.1%) and for private medical research (66.4%). Major predictors of a positive attitude towards data donation included (i) sufficient appreciation of the respective kind of research (i.e. public or private), (ii) a reciprocity attitude that patients who benefit from research have a duty to support research, and (iii) sufficient trust in data protection and data control.
Conclusion
People’s attitude towards data donation to medical research is generally positive in Germany and depends upon factors that can be curbed by legislation and internal rules of procedure. Worthy of note, designing data donation in the form of an opt-out regulation does not necessarily mean that the paradigm of informedness has to be abandoned. Rather the process of information provision must be shifted towards the creation of basic knowledge in the general population about the risks and benefits of data-intensive medical research (‘health data literacy’).

Beware: Processing of Personal Data—Informed Consent Through Risk Communication

Beware: Processing of Personal Data—Informed Consent Through Risk Communication
Lukas Seiling, Rita Gsenger, Filmona Mulugeta, Marte Henningsen, Lena Mischau, Marie Schirmbeck
IEEE, 14 March 2024
Open Access
Abstract
Background
The General Data Protection Regulation (GDPR) has been applicable since May 2018 and aims to further harmonize data protection law in the European Union. Processing personal data based on individuals’ consent is lawful under the GDPR only if such consent meets certain requirements and is “informed,” in particular. However, complex privacy notice design and individual cognitive limitations challenge data subjects’ ability to make elaborate consent decisions. Risk-based communication may address these issues.
Literature review
Most research focuses on isolated aspects of risk in processing personal data, such as the actors involved, specific events leading to risk formation, or distinctive (context-dependent) consequences. We propose a model combining these approaches as the basis for context-independent risk communication.
Research questions
1.What are relevant information categories for risk communication in the processing of personal data online? 2. Which potentially adverse consequences can arise from specific events in the processing of personal data online? 3. How can consequences in the processing of personal data be avoided or mitigated?
Research methodology
The GDPR was examined through a systematic qualitative content analysis. The results inform the analysis of 32 interviews with privacy, data protection, and information security experts from academia, Non-Governmental Organizations, the public, and the private sector.
Results
Risk-relevant information categories, specific consequences, and relations between them are identified, along with strategies for risk mitigation. The study concludes with a specified framework for perceived risk in processing personal data.
Conclusion
The results provide controllers, regulatory bodies, data subjects, and experts in the field of professional communication with information on risk formation in personal data processing. Based on our analysis, we propose information categories for risk communication, which expand the current regulatory information requirements.

Consent as a compositional act – a framework that provides clarity for the retention and use of data

Consent as a compositional act – a framework that provides clarity for the retention and use of data
Research
Minerva C. Rivas Velarde, Christian Lovis, Marcello Ienca, Caroline. Samer, Samia Hurst
Philosophy, Ethics, and Humanities in Medicine, 6 March 2024
Open Access
Abstract
Background
Informed consent is one of the key principles of conducting research involving humans. When research participants give consent, they perform an act in which they utter, write or otherwise provide an authorisation to somebody to do something. This paper proposes a new understanding of the informed consent as a compositional act. This conceptualisation departs from a modular conceptualisation of informed consent procedures.
Methods
This paper is a conceptual analysis that explores what consent is and what it does or does not do. It presents a framework that explores the basic elements of consent and breaks it down into its component parts. It analyses the consent act by first identifying its basic elements, namely: a) data subjects or legal representative that provides the authorisation of consent; b) a specific thing that is being consented to; and c) specific agent(s) to whom the consent is given.
Results
This paper presents a framework that explores the basic elements of consent and breaks it down into its component parts. It goes beyond only providing choices to potential research participants; it explains the rationale of those choices or consenting acts that are taking place when speaking or writing an authorisation to do something to somebody.
Conclusions
We argue that by clearly differentiating the goals, the procedures of implementation, and what is being done or undone when one consent, one can better face the challenges of contemporary data-intensive biomedical research, particularly regarding the retention and use of data. Conceptualising consent as a compositional act enhances more efficient communication and accountability and, therefore, could enable more trustworthy acts of consent in biomedical science.

Ethical considerations in healthcare IT: A review of data privacy and patient consent issues

Ethical considerations in healthcare IT: A review of data privacy and patient consent issues
Review Article
Adekunle Oyeyemi Adeniyi, Jeremiah Olawumi Arowoogun, Chioma Anthonia Okolo, Rawlings Chidi, Oloruntoba Babawarun
World Journal of Advanced Research and Reviews, 22 February 2024; 21(02) pp 1660–1668
Abstract
This paper delves into the ethical considerations in healthcare Information Technology (IT), focusing on data privacy and patient consent issues. It explores the intersection of technological advancements in healthcare IT and the ethical imperatives guiding their application, specifically examining challenges in ensuring data privacy and obtaining informed consent amidst the complexities introduced by digital health technologies. Through a review of existing ethical theories, regulatory frameworks, and the implications of artificial intelligence (AI) and big data, the paper highlights technological solutions and policy recommendations to address these ethical challenges. It emphasizes the importance of balancing innovation with ethical considerations to protect patient rights and maintain trust in the healthcare system. The paper advocates for ongoing research and stakeholder engagement to evolve ethical standards aligned with technological advancements in healthcare IT.